PROCEPT BioRobotics (NASDAQ:PRCT) Trading 6.6% Higher – Here’s What Happened

PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s stock price traded up 6.6% during mid-day trading on Thursday . The company traded as high as $22.02 and last traded at $22.6570. 185,349 shares changed hands during trading, a decline of 88% from the average session volume of 1,607,998 shares. The stock had previously closed at $21.25.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms are publicizing the same pending securities class action covering investors who purchased PRCT shares between February 28, 2024, and February 25, 2026. The lead-plaintiff application deadline is September 22, 2026. These announcements are largely procedural and do not represent separate confirmed lawsuits. Kaplan Fox class-action deadline notice
• Neutral Sentiment: Recent notices from Pomerantz, Kaplan Fox, DJS Law Group, Rosen Law Firm, and other firms encourage affected shareholders to contact them or seek lead-plaintiff status. The legal process could ultimately result in investor compensation, but no outcome or settlement has been announced. Pomerantz investor alert
• Negative Sentiment: The core complaint centers on allegedly undisclosed inventory problems, weaker-than-expected handpiece sales, and repeated late-quarter discounts. One notice attributes the lawsuit to an approximately 18% stock decline following revelations about these issues, highlighting investor concerns about demand visibility, channel inventory, and management disclosures. Hagens Berman securities-fraud lawsuit notice

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Piper Sandler lowered their target price on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Leerink Partners downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. Finally, William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, PROCEPT BioRobotics has an average rating of “Hold” and an average price target of $28.00.

PROCEPT BioRobotics Price Performance

The company has a market capitalization of $1.25 billion, a PE ratio of -11.28 and a beta of 0.89. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The stock’s 50 day simple moving average is $21.29 and its 200-day simple moving average is $24.56.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.35) EPS. As a group, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood purchased 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was bought at an average price of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have sold 1,000 shares of company stock worth $28,480. 4.00% of the stock is owned by corporate insiders.

Institutional Trading of PROCEPT BioRobotics

Several hedge funds have recently modified their holdings of PRCT. B. Metzler seel. Sohn & Co. AG acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at $1,864,000. DNB Asset Management AS boosted its position in shares of PROCEPT BioRobotics by 213.9% during the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company’s stock worth $3,132,000 after acquiring an additional 67,848 shares in the last quarter. Pinnacle Associates Ltd. acquired a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth about $3,876,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of PROCEPT BioRobotics by 69.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 174,739 shares of the company’s stock worth $5,375,000 after acquiring an additional 71,832 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its stake in PROCEPT BioRobotics by 56.7% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 611,000 shares of the company’s stock worth $19,222,000 after purchasing an additional 221,000 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.